

Edgar Filing: ANTARES PHARMA INC - Form 8-K

ANTARES PHARMA INC  
Form 8-K  
May 29, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

-----

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 Or 15(D) of The  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 29, 2003

ANTARES PHARMA, INC.

-----

(Exact Name of Registrant as Specified in Charter)

Minnesota	0-20945	41-1350192
-----	-----	-----
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

707 Eagleview Boulevard, Suite 414, Exton, PA 19341

-----  
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (610) 458-6200

Not Applicable

-----  
(Former Name or Former Address, if Changed Since Last Report)

Item 9. Regulation FD Disclosure.

On May 29, 2003, Antares Pharma, Inc. issued a press release regarding its presentation at the Friedman Billings Ramsey 7th Annual Technology and Growth Investor Conference. A copy of the press release issued is attached hereto as Exhibit 99.1

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

99.1 Press Release dated May 29, 2003.

Edgar Filing: ANTARES PHARMA INC - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 29, 2003

ANTARES PHARMA, INC.

By /s/ Lawrence M. Christian

-----  
Lawrence M. Christian  
Chief Financial Officer

EXHIBIT INDEX

99.1 Press Release dated May 29, 2003.